Clinical Trials Browser

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2 Completed

40 enrolled 18 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Phase 2 Terminated

3 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT01867333 2023-09-26

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Phase 2 Completed

57 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT01995513 2023-09-18

PLATO

Phase 4 Completed

509 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2 Completed

71 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02012296 2022-07-13

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Phase 1/2 Completed

88 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Phase 2 Terminated

4 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT02090114 2022-06-27

Restore

Phase 2 Completed

112 enrolled 20 charts

Genitourinary

Prostatic Neoplasms

NCT02268175 2022-04-19

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Phase 2 Completed

75 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT02601014 2022-02-03

STARVE-PC

Phase 2 Completed

32 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02711956 2021-11-30

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

75 enrolled 31 charts

Genitourinary

Prostatic Neoplasms

NCT02508636 2021-10-12

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

Phase 2 Terminated

11 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT03478904 2021-05-10

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Phase 1 Terminated

1 enrolled 8 charts

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02685267 2021-04-09

Doce/Enza

Phase 2 Terminated

9 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT03418324 2020-12-30

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Phase 2 Completed

11 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Phase 2 Completed

49 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02064582 2020-10-12

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

Phase 2 Completed

7 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT01875250 2020-09-16

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Phase 2 Completed

38 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

CELLO-1

Tivozanib + Enzalutamide in Adv Prostate Cancer

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

PROSPER

CheckMate 9KD

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

SPLASH

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

STEEL

CONTACT-02

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

ARROW

KEYNOTE-641

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

KEYLYNK-010

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

PRESIDE

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

ENACT

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

PLATO

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Restore

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

STARVE-PC

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Doce/Enza

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer